SCHEMBL3071050

SCHEMBL3071050

CNC(=S)c1cc(C(=O)OC)cc(-c2ccc(C)cn2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.40
NR1I2 O75469 3/20 0.39
ATM Q13315 1/20 0.38
CYP2C9 P11712 1/20 0.38
P2RX3 P56373 5/20 0.38
P2RX2 Q9UBL9 5/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2A6 P11509 1/20 0.38
BAZ2B Q9UIF8 1/20 0.37
CCR1 P32246 1/20 0.37
CCR5 P51681 1/20 0.37
CCR8 P51685 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
CNR2 P34972 1/20 0.36
P2RX7 Q99572 1/20 0.36
RAB9A P51151 2/20 0.36
NPC1 O15118 1/20 0.36
CYP46A1 Q9Y6A2 1/20 0.36
ALPL P05186 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1495784 0.89 TDP1 (0.49) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL3070661 0.88 NR1I2 (0.41) NR1I2CYP2C9P2RX3P2RX2CYP3A4
SCHEMBL3058393 0.87 BAZ2B (0.48) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL3071034 0.87 BAZ2B (0.42) NR1I2CYP2C9P2RX3P2RX2CYP3A4
SCHEMBL3066007 0.84 KDM4E (0.48) TDP1NR1I2ATMP2RX3P2RX2
SCHEMBL7947936 0.84 CNR2 (0.48) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL3069110 0.82 TDP1 (0.41) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL1495521 0.82 CA12 (0.51) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL3067384 0.81 NR1I2 (0.41) TDP1NR1I2ATMCYP2C9P2RX3
SCHEMBL1495743 0.81 RXFP1 (0.45) TDP1NR1I2ATMCYP2C9P2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2215049-B1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME (US) 2019-06-12 EP disclosed
US-8247401-B2 P2X3 receptor antagonists for treatment of pain MERCK SHARP & DOHME CORP. (US) 2012-08-21 US disclosed
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK SHARP & DOHME LLC 2010-10-21 US disclosed
EP-2215049-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN Merck Sharp & Dohme Corp. (US) 2010-08-11 EP disclosed
WO-2009058298-A1 P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN MERCK & CO., INC. (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100266714-A1 P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN P2RX3, P2RX1, P2RX2 TDP1 1765/4885NR1I2 598/4885ATM 4263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.